Anacor Pharmaceuticals (ANAC)
Create an AlertANAC Key Stats
| Income Statement | |
| Revenue TTM | 10.74M |
| Revenue Quarterly YoY Growth | 26.66% |
| EPS Diluted TTM | -1.770 |
| EPS Diluted Quarterly YoY Growth | |
| Net Income TTM | -56.09M |
| Profitability | |
| Gross Profit Margin Quarterly | |
| Profit Margin Quarterly | -379.4% |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 186.77M |
| Enterprise Value | 166.93M |
| PE Ratio TTM | |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 38.82 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 5.335 |
| Free Cash Flow | -11.55M |
| Return on Equity | -702.0% |
ANAC News
- Anacor Pharma (ANAC) Enters $45M Term Loan with Hercules Tech (HTGC) Street Insider Jun 12
- Anacor Pharmaceuticals Secures $45 Million Loan Facility Business Wire Jun 12
- ANACOR PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitiv... Jun 12
- Anacor Pharmaceuticals is Now Oversold (ANAC) Jun 6
- ANACOR PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote... Jun 5
- Anacor Pharmaceuticals: A Small Cap With Tremendous Upside And Multiple Short To... Jun 4
- Nasdaq stocks posting largest percentage increases May 30
- ANAC's Discussion with FDA for Tavaborole May 30
- ANAC's Discussion with FDA for Tavaborole - Analyst Blog Zacks May 30
- Anacor Pharma (ANAC) Completes pre-NDA for Tavaborole Street Insider May 29
ANAC Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Anacor Pharmaceuticals is up 2.78% over the last year vs S&P 500 Total Return up 23.89%, QLT up 7.47%, and Valeant Pharmaceuticals International up 87.43%.
ANAC Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these ANAC related companies
Pro Ratings for ANAC
Pro Report PDF for ANAC
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download ANAC Pro Report PDF
Pro Strategies Featuring ANAC
Did Anacor Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
ANAC Profile
Sector: Healthcare
Industry: Biotechnology
Other ANAC Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ANAC | 5.18 | -0.02 | -0.38% | 186.77M |
